Moreover, combined GSK3 and PARP inhibition has yielded encouraging results in BRCA2 deficient or HR proficient colon cancer cells but not on BRCA1 deficient breast cancer HCC1937 cells. This evidence concerns the gene PARP1 and colonic neoplasm.